2. Search Result
Search Result
Results for "

O-GlcNAcase

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

1

Natural
Products

1

Recombinant Proteins

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12588
    Thiamet G
    45+ Cited Publications

    		 OGA Autophagy Cancer
    Thiamet G is a potent and selective inhibitor of O-GlcNAcase (OGA), which acts to remove O-GlcNAc from modified proteins, with Ki of 20 nM for human OGA.
    Thiamet G
  • HY-108241
    (Z)-PUGNAc
    4 Publications Verification

    		 OGA Metabolic Disease
    (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form .
    (Z)-PUGNAc
  • HY-139431
    NAG-thiazoline

    		OGA Bacterial Infection
    NAG-thiazoline is a O-GlcNAcase inhibitor with a Ki of 180 nM. NAG-thiazoline is a potent GH20 GlcNAcase (VhGlcNAcase) inhibitor with an IC50 of 11.9 μM and a Ki of 62 µM .
    NAG-thiazoline
  • HY-145934A
    UDP-GlcNAz disodium

    		OGT Biochemical Assay Reagents Glycosidase Metabolic Disease
    UDP-GlcNAz disodium is the analogue of UDP-GlcNAc disodium (HY-112174). UDP-GlcNAc disodium is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GlcNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GlcNAc disodium is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
    UDP-GlcNAz disodium
  • HY-130121
    MK-8719

    		OGA Neurological Disease
    MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (Ki=7.9 nM for hOGA) with excellent CNS penetration .
    MK-8719
  • HY-144681
    Ceperognastat

    LY3372689

    		 OGA Tau Protein Neurological Disease
    Ceperognastat (LY3372689) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. Ceperognastat can be used for tauopathies research, including Alzheimer’s disease .
    Ceperognastat
  • HY-156586
    Egalognastat

    ASN90

    		 OGA Tau Protein Neurological Disease
    Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .
    Egalognastat
  • HY-139793
    UDP-glucosamine disodium

    		OGT Endogenous Metabolite Metabolic Disease
    UDP-glucosamine (UDP-GlcNAc) disodium is a substrate for O-GlcNAc transferase, which catalyzes the attachment of O-GlcNAc to proteins. O-GlcNAcase catalyzes the removal of O-GlcNAc from proteins. UDP-glucosamine (UDP-GlcNAc) disodium is the end product of the hexosamine biosynthesis pathway, which is regulated primarily by glucose-6-phosphate-Glutamine:fructose-6-phosphate amidotransferase (GFAT) .
    UDP-glucosamine disodium
  • HY-131979
    TP-040

    O-GlcNAcase-IN-1

    		 OGA Neurological Disease
    TP-040 (O-GlcNAcase-IN-1), a chemical probe, is a potent and novel OGA inhibitor with an IC50 value of 46 nM.
    TP-040
  • HY-176852
    O-GlcNAcase-IN-3

    		OGA Neurological Disease
    O-GlcNAcase-IN-3 (Compound I) is an OGA inhibitor. O-GlcNAcase-IN-3 can be used for Alzheimer's Disease (AD) research .
    O-GlcNAcase-IN-3
  • HY-149552
    Ac4-5SGlcNAc

    		OGT Cancer
    Ac4-5SGlcNAc is an O-GlcNAc transferase (OGT) inhibitor. Ac4-5SGlcNAc converts intracellularly to UDP-5SGlcNAc, which competes with native UDP-GlcNAc (HY-148596) to block OGT catalytic activity, reduces cellular UDP-GlcNAc pools, and limits global protein O-GlcNAcylation. Ac4-5SGlcNAc reduces OGA levels via feedback, alters lectin signal intensities and glycan-related band masses. Ac4-5SGlcNAc can be used for the research of breast cancer .
    Ac4-5SGlcNAc
  • HY-E71360
    O-GlcNAcase, Clostridium perfringens

    		Glycosidase Others
    O-GlcNAcase, Clostridium perfringens is a glycosidase derived from Clostridium perfringens, which functions in bacterial nutrient metabolism, host interaction and virulence regulation. O-GlcNAcase is a core enzyme in the cellular signal regulatory network and serves as a key target for various major and chronic diseases. O-GlcNAcase, Clostridium perfringens can be used for basic research and drug development of O-GlcNAcase due to its high conservation in catalytic mechanism and structure with human-derived enzymes .
    O-GlcNAcase, Clostridium perfringens
  • HY-145934B
    UDP-GlcNAz

    		OGT Biochemical Assay Reagents Glycosidase Metabolic Disease
    UDP-GlcNAz is the analogue of UDP-GlcNAc disodium (HY-112174). UDP-GlcNAc disodium is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GlcNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GlcNAc disodium is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
    UDP-GlcNAz
  • HY-144682
    (2R,4R)-LY3372689

    		OGA Neurological Disease
    O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease .
    (2R,4R)-LY3372689
  • HY-181600
    O-GlcNAcase-IN-4

    		OGA Neurological Disease
    O-GlcNAcase-IN-4 (compound T-110) is a O-GlcNAcase inhibitor. O-GlcNAcase-IN-4 modulates the activity of O-GlcNAcase. O-GlcNAcase-IN-4 is applicable to the research of neurodegenerative diseases and disorders, Alzheimer's disease, and tau-mediated neurodegenerative diseases or disorders .
    O-GlcNAcase-IN-4
  • HY-161953
    O-GlcNAcase-IN-2

    		OGA Neurological Disease
    O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects .
    O-GlcNAcase-IN-2
  • HY-183557
    O-GlcNAcase-IN-6

    		OGA Neurological Disease
    O-GlcNAcase-IN-6 is an orally active, blood-brain barrier-permeable O-GlcNAcase (OGA) inhibitor with an IC50 of 5.4 nM. O-GlcNAcase-IN-6 inhibits OGA activity, thereby increasing the level of O-GlcNAc glycosylation in brain tissues. O-GlcNAcase-IN-6 can be used for the research of Alzheimer's disease .
    O-GlcNAcase-IN-6
  • HY-185146
    O-GlcNAcase-IN-5

    		OGA Tau Protein Neurological Disease
    O-GlcNAcase-IN-5 (Compound 1) is a selective O-GlcNAcase inhibitor. O-GlcNAcase-IN-5 can prevent the enzyme from removing the O-GlcNAc modification on tau protein, thus avoiding excessive phosphorylation of tau protein. O-GlcNAcase-IN-5 can be used for the research of Alzheimer's disease .
    O-GlcNAcase-IN-5
  • HY-144681A
    rel-Ceperognastat

    rel-LY3372689

    		 OGA Tau Protein Neurological Disease
    rel-Ceperognastat (rel-LY3372689) (Compound Formula Ic) is a O-GlcNAcase (OGA) inhibitor that can be used to study the neurodegenerative diseases and disorders, such as Alzheimer's disease .
    rel-Ceperognastat
  • HY-108241R
    (Z)-PUGNAc (Standard)

    		OGA Reference Standards Metabolic Disease
    (Z)-PUGNAc (Standard) is the analytical standard of (Z)-PUGNAc (HY-108241). This product is intended for research and analytical applications. (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form .
    (Z)-PUGNAc (Standard)
  • HY-P10572
    HG1 Toxin

    		Ser/Thr Protease Potassium Channel Inflammation/Immunology Endocrinology
    HG1 Toxin is a peptide found in the venom of the scorpion Heterometrus fulvipes, which has the activity of inhibiting potassium channel Kv1.3. HG1 Toxin also has the activity of inhibiting trypsin (Ki=107 nM) and can be used in the study of autoimmune diseases .
    HG1 Toxin
  • HY-108241A
    Galacto-PUGNAc

    		Glycosidase Neurological Disease
    Galacto-PUGNAc is a selective competitive inhibitor of lysosomal β-hexosaminidases (HEX), with Ki values of 51 and 18 nM, for hHEXA and hHEXB, respectively. Galacto-PUGNAc elevates GM2 ganglioside levels in neuroblastoma cells. Galacto-PUGNAc can be used for the research of neurodegenerative disorders .
    Galacto-PUGNAc

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: